GH Research (NASDAQ:GHRS) Shares Gap Up to $12.25

GH Research PLC (NASDAQ:GHRSGet Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $12.25, but opened at $12.55. GH Research shares last traded at $12.47, with a volume of 8,822 shares changing hands.

Wall Street Analysts Forecast Growth

GHRS has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of GH Research in a research report on Tuesday, May 7th. JMP Securities lowered their target price on GH Research from $50.00 to $39.00 and set a “market outperform” rating on the stock in a research report on Friday, March 1st. Finally, Canaccord Genuity Group lifted their target price on GH Research from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, May 6th.

Check Out Our Latest Stock Analysis on GHRS

GH Research Stock Down 1.4 %

The stock has a market cap of $628.00 million, a P/E ratio of -19.47 and a beta of 0.91. The business has a 50 day moving average price of $12.05 and a two-hundred day moving average price of $8.96.

GH Research (NASDAQ:GHRSGet Free Report) last announced its quarterly earnings results on Friday, May 3rd. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. On average, research analysts forecast that GH Research PLC will post -0.84 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GHRS. Lynx1 Capital Management LP boosted its stake in GH Research by 80.1% during the first quarter. Lynx1 Capital Management LP now owns 3,310,563 shares of the company’s stock valued at $35,291,000 after buying an additional 1,471,946 shares during the last quarter. RTW Investments LP boosted its stake in GH Research by 53.4% during the third quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock valued at $33,438,000 after buying an additional 1,158,172 shares during the last quarter. BVF Inc. IL lifted its stake in shares of GH Research by 12.1% in the 4th quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after purchasing an additional 1,125,000 shares during the last quarter. RA Capital Management L.P. lifted its stake in shares of GH Research by 11.9% in the 1st quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock valued at $66,643,000 after purchasing an additional 664,381 shares during the last quarter. Finally, Barclays PLC lifted its stake in shares of GH Research by 98.2% in the 3rd quarter. Barclays PLC now owns 63,590 shares of the company’s stock valued at $640,000 after purchasing an additional 31,500 shares during the last quarter. 56.90% of the stock is owned by institutional investors.

GH Research Company Profile

(Get Free Report)

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

Further Reading

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.